Although candesartan and telmisartan exhibited weaker inverse agonist activity for N111G-compared with WT-AT 1 receptors, only eprosartan exhibited robust inverse agonist activity for both N111G-and WT-AT 1 receptors. Specific ligand-receptor contacts for candesartan and telmisartan are altered in the active-state N111G-AT 1 receptors compared with the ground-state WT-AT 1 receptors, suggesting an explanation of their attenuated inverse agonist activity for the active state of AT 1 receptors. In contrast, interactions between eprosartan and N111G-AT 1 receptors were not significantly altered, and the inverse agonist activity of eprosartan was robust.
Introduction
GPCRs comprise one of the largest superfamilies of integral membrane proteins in the human genome and are commonly characterized by their seven-transmembrane (TM) α-helix structure (Fredriksson et al., 2003) . GPCRs respond to a wide variety of ligands, such as photons, tastants, ions, monoamines, purines, lipids, peptides and proteins, promoting intracellular signalling cascades in numerous physiological and pathological processes. It has been reported that~26% of commercially available drugs are known to target GPCRs (Garland, 2013) .
The angiotensin II (Ang II) AT 1 receptor belongs to the rhodopsin family of GPCRs and is involved in the regulation of various physiological and pathological processes. For example, physiological activation of AT 1 receptors regulates vascular tone, water-electrolyte balance and cardiac function and maintains cardiovascular homeostasis. However, excessive AT 1 receptor activation causes a wide variety of human diseases, such as hypertension, cardiac hypertrophy, coronary artery disease, stroke and diabetic nephropathy (Khan, 2011; Vijayaraghavan and Deedwania, 2011; Lee et al., 2012; Vejakama et al., 2012) . Although the AT 1 receptor is traditionally activated by its agonist Ang II, recent studies revealed that mechanical stress and AT 1 receptor-directed autoantibodies can activate this receptor without the need for Ang II stimulation, in diseases such as hypertension, cardiac hypertrophy, pre-eclampsia, graft rejection for renal transplantation, primary aldosteronism and systemic sclerosis (Mederos y Schnitzler et al., 2011; Riemekasten et al., 2011; Storch et al., 2012; Unal et al., 2012; Rossitto et al., 2013; Gunther et al., 2014; Wallukat and Schimke, 2014; Li et al., 2015) . Therefore, robust blockade of AT 1 receptors in the clinical setting requires not only antagonist activity against Ang II binding but also robust inverse agonist activity for the Ang II-independent active state of AT 1 receptors, to yield enhanced therapeutic effects against the various disease states.
As described in our recent study, the most commonly prescribed AT 1 receptor blockers (ARBs), namely, losartan, EXP3174, valsartan and irbesartan, exhibit robust inverse agonist activity for the ground state of AT 1 receptors. However, the inverse agonist activity of these four ARBs strongly decreases upon transition of AT 1 receptors to the active state (Takezako et al., 2015) . A robust inverse agonist towards the active state of AT 1 receptors has not yet been discovered.
Most ARBs exhibit a common chemical structure, namely, a biphenyl-tetrazole moiety, and are therefore referred to as biphenyl-tetrazole ARBs ( Figure 1A) . Candesartan, olmesartan, azilsartan, losartan, EXP3174, valsartan and irbesartan belong to this biphenyl-tetrazole class of ARBs. Among these, candesartan exhibits two unique structural features, namely, a benzimidazole ring and an ethoxy group substituent on the imidazole core ( Figure 1A) , and is known to cause insurmountable antagonism of AT 1 receptors (Fierens et al., 1999; Takezako et al., 2004) . Telmisartan is a non-biphenyl-tetrazole ARB and is also known to cause insurmountable antagonism of AT 1 receptors (Le et al., 2007) . Telmisartan contains a carboxyl group instead of a tetrazole moiety at the 2 0 -position of the biphenyl moiety, in addition to bulky bis-benzimidazole rings ( Figure 1A ). Eprosartan is an also non-biphenyl-tetrazole ARB and is known to cause surmountable antagonism of AT 1 receptors (Timmermans, 1999) . Eprosartan exhibits a unique structure composed of carboxyphenyl and thiophenepropanoic acid moieties ( Figure 1A ). In this study, we have examined whether these structural differences affect the inverse agonist activities of candesartan, telmisartan and eprosartan for the ground and active states of AT 1 receptors . Specifically, we determined how the transition of AT 1 receptors to the active-state influences the inverse agonist activities of these ARBs and found that the non-biphenyl-tetrazole ARB eprosartan is a unique and robust inverse agonist for the active state of AT 1 receptors.
Methods

Mutagenesis, expression and membrane preparation
The synthetic rat AT 1 receptor gene, cloned in the shuttle expression vector pMT-3, was used for expression and mutagenesis, as previously described (Noda et al., 1996) . Residues previously identified as ARB-binding site residues were mutated. For each mutation, we substituted amino-acid residues with residues containing a side chain of nearly the same size and/or chemical characteristics, as previously described (Takezako et al., 2015) . For expression of AT 1 receptors, 10 μg of purified plasmid DNA was transfected into same passage of COS-1 cells for each experiment. Since experiment was performed in same cells, our samples do not need to be randomized. Membranes were prepared by transfecting COS-1 cells cultured in DMEM supplemented with 10% FBS using the FuGENE6 transfection reagent. The transfected cells were cultured for 48 h and subsequently harvested. Cell membranes were prepared using the nitrogen Parr bomb disruption method in the presence of protease inhibitors. carried out under equilibrium conditions, as previously described (Takezako et al., 2004) .
Inositol phosphate production assay
The inositol phosphate (IP) production assay was carried out as previously described (Takezako et al., 2015) . Briefly, semiconfluent AT 1 receptor-transfected COS-1 cells were seeded in six-well plates and subsequently labelled with myo-[2-3 H(N)]-inositol (1.5 μCi·mL À1 ; specific activity, 22 μCi·mol À1 ) for 24 h at 37°C in DMEM supplemented with 10% FBS. Labelled cells were washed twice with DMEM and subsequently incubated with DMEM containing 10 mM LiCl and vehicle or one of the various ARBs for 120 min at 37°C. Following incubation, the medium was removed, and perchloric acid was used to extract the total soluble IP from the cells, as previously described (Noda et al., 1996) . EC 50 and IC 50 values were determined by non-linear regression analysis using GraphPad Prism. The inverse agonist activities of the ARBs were calculated for each AT 1 receptor mutant as a percent of receptor activity of vehicle-treated cells expressing each AT 1 receptor mutant (constitutive activity of each mutant). We defined the constitutive activity of each mutant receptor in vehicle-treated cells as 0%. Therefore, an inverse agonist activity of À10% reflects a constitutive activity of 90%, while an inverse agonist activity of À100% reflects a constitutive activity of 0%. In other words, an inverse agonist activity of À100% reflects complete suppression of constitutive activity for the examined wild-type (WT) or mutant AT 1 receptor.
Models of AT 1 receptor ARB-binding pockets
Models of the ligand-binding pockets for candesartan, telmisartan and eprosartan were constructed as described in Zhang et al. (2015) . The AT 1 receptor crystal structure was used to dock the ARBs via an energy-based docking protocol using the ICM molecular modelling software suite from
Figure 1
Structures of ARBs and AT 1 receptors. (A) The chemical structures of losartan, valsartan, candesartan, irbesartan, telmisartan and eprosartan. Four of the six ARBs exhibit a common structure, namely, a biphenyl-tetrazole moiety, while telmisartan and eprosartan are non-biphenyl-tetrazole ARBs. (B) Secondary structure model of rat AT 1 receptors, revised on the basis of the crystal structure of human AT 1 receptors. Residues that are numbered and highlighted in yellow indicate residues mutated in this study. The epitope tag attached to the C-terminus in underlined and allowed for detection by the ID4 monoclonal antibody.
Molsoft (San Diego, CA, USA). The initial model for each ARB was first optimized by adding side-chain hydrogen atoms, followed by optimization of the resultant conformations and subsequent generation of soft potential maps in a 30 × 30 × 30 Å 3 box, which covered the extracellular half of the AT 1 receptor. Two-dimensional representations of the compounds were used to generate the molecular models, and their three-dimensional geometry was optimized using the MMFF-94 force field (Halgren, 1995) . Biased probability Monte Carlo optimization of the internal coordinates of the ligand in the grid potentials of the receptor was employed for molecular docking (Abagyan and Totrov, 1997) . Five independent docking runs were carried out for each ligand starting from a random conformation. Monte Carlo sampling and optimization were performed with the high thoroughness parameter set to 30. The Lys199 5.42 side chain was treated as a flexible group in the receptor, allowing this side chain's rotamers to freely sample the space. Up to 30 alternative complex conformations of the ligand-receptor complex were generated. The conformations were rescored using the ICM binding score function, which accounts for van der Waals, electrostatic, H-bonding, non-polar and polar atom solvation energy differences between bound and unbound states, ligand internal strain, conformational entropy and ligandindependent and receptor-independent constants. The results of individual docking runs for each ligand were considered consistent if at least three of the five docking runs produced similar conformations (RMSD <2.0 Å) and binding scores of <À20.0 kJ·mol
À1
. No distance restraints or any other a priori derived information for the ligand-receptor interactions were used in the unbiased docking procedure.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All data are presented as mean ± SEM. Multiple comparisons were made using a one-way ANOVA followed by Bonferroni's or Dunnett's post hoc tests using StatView Software (SAS Institute Inc., Cary, NC, USA) as statistical program. P values of <0.05 were considered to be statistically significant. Although operator and data analyst were not blinded, analysed data were confirmed by other co-authors. 
Materials
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
Eprosartan is a unique and robust inverse agonist for the active state of AT 1 receptors
We investigated the binding affinities of ARBs for both WT-AT 1 receptors, which are representative of the ground-state receptor, and the constitutively active N111G mutant of the AT 1 receptor (N111G-AT 1 receptor), which mimics the active state of AT 1 receptors (Boucard et al., 2003; Martin et al., 2004; Martin et al., 2007; Unal et al., 2013) . The pharmacological properties of losartan, valsartan, irbesartan, candesartan, telmisartan and eprosartan were compared for both WTand N111G-AT 1 receptors. Data for losartan, valsartan and irbesartan were taken from our recent study (Takezako et al., 2015) . The binding affinities of all six ARBs were higher for WT-AT 1 receptors than for N111G-AT 1 receptors. The order of binding affinity for WT-AT 1 receptors was determined to be candesartan > irbesartan > telmisartan > valsartan = eprosartan > losartan (Table 1) (Takezako et al., 2015) . In contrast, the order of binding affinity for N111G-AT 1 receptors was candesartan > irbesartan > telmisartan > eprosartan > valsartan > losartan (Table 2) (Takezako et al., 2015) . The inverse agonist activity of all six ARBs increased in a concentration-dependent manner for both WT-and N111G-AT 1 receptors (Figure 2 ). The order of potency of the six ARBs for WT-AT 1 receptors was candesartan > valsartan = irbesartan = telmisartan > eprosartan > losartan ( Figure 2A ). In contrast, the order of potency of the six ARBs for N111G-AT 1 receptors was candesartan > irbesartan > telmisartan > valsartan > losartan > eprosartan (Figure 2A ). Although five of the six ARBs exhibited weaker maximal inverse agonist activity for N111G-AT 1 receptors compared with the WT receptors, only eprosartan exhibited robust inverse agonist activity for both N111G-and WT-AT 1 receptors ( Figure 2B ). Thus, we identified eprosartan as a unique and robust inverse agonist of the active state of AT 1 receptors.
Identification of ARB-binding residues of WT-AT 1 receptors
To identify the amino-acid residues involved in ligand binding to WT-AT 1 receptors, we examined the effects of various mutations introduced in the WT-receptor on the binding affinities of candesartan, telmisartan and eprosartan (Table 1 ). All mutants introduced in the WT-AT 1 receptors are known to alter the binding affinity and/or inverse agonist activity of the biphenyl-tetrazole ARBs (Takezako et al., 2015) , because these mutants might be predicted to alter the binding affinities of not only candesartan but also telmisartan and eprosartan. As mutation of some non-interacting residues could result in small reductions in ligand binding affinity, we used the effect of a known change to set a threefold change as the cut-off for reduction in binding affinity, as previously described (Takezako et al., 2015) . The mutations V108I, S109T, Y113A, A163T, F182A, K199A, K199Q, H256A Q257A, Q257E, Y292A and N295A reduced the binding affinity of candesartan. The mutations V108I, S109T, Y113A, Q257A, Q257E and N295A reduced the binding affinity of telmisartan, whereas A163T and Y184A mutations increased the binding affinity of telmisartan. The mutations V108I, Y113A, K199A, H256A, Q257A, Q257E, Y292A and N295A reduced the binding affinity of eprosartan. helices, we selected combinations of S109T, A163T, K199Q, H256A and N295A mutations to evaluate the combined effects of different TM helices on both binding affinity and inverse agonism, as previously described (Takezako et al., 2015) . The S109T/N295A mutation synergistically reduced the binding affinities of candesartan and eprosartan and additively reduced the binding affinity of telmisartan. The A163T/N295A mutation synergistically reduced the binding affinity of candesartan. The S109T/H256A, K199Q/H256A and H256A/N295A mutations synergistically reduced the binding affinity of eprosartan. 
Identification of ARB-binding residues of N111G-AT 1 receptors
To identify the amino-acid residues in N111G-AT 1 receptors involved in ligand binding, we examined the effects of various mutations introduced in these receptors on the binding affinities of candesartan, telmisartan and eprosartan (Table 2 ). All mutants introduced in the N111G-AT 1 receptors alter the binding affinity and/or inverse agonist activity of Table 1 Binding properties of ARBs for the WT-AT 1 receptors and various mutants the biphenyl-tetrazole ARBs (Takezako et al., 2015) , because these mutants might be predicted to alter the binding affinities of not only candesartan but also telmisartan and eprosartan. As previously described, the N111G/Y113A mutant did not show any detectable binding activity, so that the effects of this mutant could not be examined (Takezako et al., 2015) . The effects of most of the examined N111G-AT 1 receptor mutants on the binding affinities of the three ARBs were quite different from those observed for WT-AT 1 receptor mutants. The mutations N111G/V108I, N111G/S109T, N111G/A163T, N111G/K199A, N111G/K199Q, N111G/ Q257A, N111G/Q257E and N111G/N295A reduced the binding affinity of candesartan. However, the effects of other N111G-AT 1 receptor mutants on the binding affinity of candesartan were different from those observed for WT-AT 1 receptor mutants. Contrary to the effects observed for the F182A, H256A and Y292A mutations in WT-AT 1 receptor, the N111G/F182A and N111G/H256A mutations did not reduce the binding affinity of candesartan, while the N111G/Y292A mutation increased the binding affinity of candesartan. The mutations N111G/V108I, N111G/S109T, N111G/Q257E and N111G/N295A reduced the binding affinity of telmisartan. However, the effects of other N111G-AT 1 receptor mutants on the binding affinity of telmisartan were different from those observed for WT-AT 1 receptor mutants. Two additional mutations, namely, N111G/K199A and N111G/K199Q, reduced the binding affinity of telmisartan. Contrary to the effects observed for the A163T, Y184A and Q257A mutations in WT-AT 1 receptors, the N111G/A163T mutation increased the binding affinity of telmisartan, while the N111G/Y184A and N111G/Q257A mutations did not alter the binding affinity of telmisartan. Contrary to the effects observed for the Y292A mutation in WT-AT 1 receptors, the N111G/Y292A mutation increased the binding affinity of telmisartan. The mutations N111G/V108I, N111G/K199A, N111G/K199Q, N111G/H256A, N111G/Q257A, N111G/Q257E and N111G/ N295A reduced the binding affinity of eprosartan. However, the effects of other N111G-AT 1 receptor mutants on the binding affinity of eprosartan were different from those observed for WT-receptor mutants. Contrary to the effects observed for the Y292A mutation in WT-AT 1 receptor, the N111G/Y292A mutation did not alter the binding affinity of eprosartan. and Asn295 TM7 are involved in eprosartan binding.
To resolve the putative interactions between the residues in N111G-AT 1 receptors involved in the binding of candesartan, telmisartan and eprosartan, we examined the effects of seven triple mutations on the binding affinities of all three ARBs ( Table 2 ). The N111G/S109T/N295A mutation synergistically reduced the binding affinity of candesartan and additively reduced the binding affinities of telmisartan and eprosartan. The N111G/K199Q/H256A mutation synergistically reduced the binding affinities of candesartan and eprosartan. The N111G/S109T/H256A mutation additively reduced the binding affinities of eprosartan. Contrary to the effects observed for the H256A/N295A mutation, the N111G/H256A/N295A mutation did not show combined effects on the binding affinity of eprosartan. No other triple mutations exhibited combined effects on the binding affinities of any of the three ARBs. These results indicate that interactions between Ser109 and Asn295 in N111G-AT 1 receptors are important for binding of all three ARBs and that interactions between Ser109 and His256 are important for eprosartan binding, while interactions between Lys199 and His256 are important for both candesartan and eprosartan binding.
Critical residues in WT-AT 1 receptors responsible for the inverse agonist activities of candesartan, telmisartan and eprosartan
To identify the critical amino-acid residues in WT-AT 1 receptors responsible for the inverse agonist activities of candesartan, telmisartan and eprosartan, we examined the effects of various mutations introduced in these WT-receptors on the inverse agonist activities of the ARBs. As previously shown, the V108I, S109T, A163T, E173A, F182A, Q257A, Y292A and N295A mutations demonstrated sufficient constitutive activity (Takezako et al., 2015) , and thus, the effects of these mutations on inverse agonism were examined
Figure 2
Differences in the inverse agonist activities of the six ARBs for WT-AT 1 receptors and the N111G-AT 1 receptor mutant, as measured by the IP assay. The concentration-dependent inverse agonist activities of losartan, valsartan, candesartan, irbesartan, telmisartan and eprosartan for (A) WT-AT 1 receptors and (B) N111G-AT 1 receptors transfected into COS-1 cells. Maximal inverse agonist activities of losartan, valsartan, candesartan, irbesartan, telmisartan and eprosartan for (C) WT-AT 1 receptors and (D) N111G-AT 1 receptors, measured at a concentration of 10 μM for each ARB. Data for losartan, valsartan and irbesartan are taken from our recent study and used with permission from Molecular Pharmacology (Takezako et al., 2015) . The inverse agonist activities of the six ARBs are expressed as a percentage of the constitutive activity of vehicle-treated WT-AT 1 receptor-transfected and N111G-AT 1 receptor-transfected COS-1 cells. The constitutive activities of vehicle-treated cells expressing WT-AT 1 receptors and N111G-AT 1 receptors were defined as 0%. Data represent mean ± SEM of independent experiments (n = 6 for each groups).
* P < 0.05, significant differences between the groups; one-way ANOVA followed by Bonferroni's or Dunnett's post hoc tests.
( Figure 3) . As the Y113A, K199A, K199Q and H256A mutations displayed only subtle constitutive activity, the effects of these mutations on inverse agonism could not be examined. The S109T, F182A, Q257A, Y292A and N295A mutations significantly decreased the inverse agonist activity of candesartan. To elucidate the combinational interactions between the residues in WT-AT 1 receptors responsible for the inverse agonist activities of candesartan, telmisartan and eprosartan, the effects of double mutations on the inverse agonist activities were examined. The S109T/A163T, S109T/N295A and A163T/N295A mutations demonstrated sufficient constitutive activity, as previously described (Takezako et al., 2015) , and thus, the effects of these mutations on the inverse agonist activities were examined (Figure 3) . The S109T/N295A mutation additively decreased the inverse agonist activities of all three ARBs. The A163T/N295A mutation additively decreased the inverse agonist activity of candesartan and synergistically decreased the inverse agonist activity of eprosartan. The S109T/A163T mutation did not demonstrate any combined effects on the inverse agonist activities of any of the three ARBs. These results suggest that combinational interactions between Ser109 TM3 and Asn295 TM7 in WT-AT 1 receptors are important for the inverse agonist activities of all three ARBs, while those between Ala163 TM4 and Asn295 TM7 are important for the inverse agonist activities of candesartan and eprosartan.
Critical residues in N111G-AT 1 receptors responsible for the inverse agonist activities of candesartan, telmisartan and eprosartan
To identify the critical residues in N111G-AT 1 receptors responsible for the inverse agonist activities of the various ARBs, the effects of various mutations introduced in the N111G-receptors on inverse agonist activities were examined. All mutations showed significantly higher constitutive activity than WT-AT 1 receptors, as previously described (Takezako et al., 2015) , and thus, the effects of these mutations on the inverse agonist activities were examined (Figure 4) . The effects of different mutations in N111G-AT 1 receptors on the inverse agonist activities of the three ARBs were quite different from those observed for different mutations in the WT-receptors. The N111G/S109T, N111G/F182A and N111G/Q257A mutations significantly decreased the inverse agonist activity of candesartan. However, the effects of other mutations in Figure 3 Effects of the AT 1 receptor mutants on the inverse agonist activities of candesartan, telmisartan and eprosartan in cells expressing various mutants of WT-AT 1 receptors, as measured by the IP assay. The inverse agonist activities of (A) candesartan, (B) telmisartan and (C) eprosartan at a concentration of 10 μM for each ARB in COS-1 cells transfected with WT-AT 1 receptors, single mutants and double mutants are shown. The double mutants were constructed using two independent mutants that significantly attenuated the inverse agonist activity. The inverse agonist activities are expressed as a percentage of the constitutive activity of either WT-AT 1 receptors or each mutant. The constitutive activities of the vehicle-treated cells expressing WT-AT 1 receptors and each mutant were defined as 0% for each. Data represent mean ± SEM of independent experiments [candesartan: n = 8 (WT-AT 1 receptor) and n = 6 (all mutants); telmisartan: n = 12 (Y292A), n = 10 (WT-AT 1 receptor, E173A and Q257A), n = 8 (N295A) and n = 6 (all other mutants); and eprosartan: n = 12 (WT-AT 1 receptor), n = 10 (E173A, Q257A, Y292A and N295A) and n = 6 (all other mutants)]. Group sizes are not equal in Figure 3 . The reason for this is that data of some groups showed large SEM when n = 6 per group, and we had to examine additional experiments to confirm exact value for these groups. * P < 0.05, significant difference from WT-AT 1 receptors †, additive effect; one-way ANOVA followed by Bonferroni's or Dunnett's post hoc tests.
Figure 4
Effects of N111G-AT 1 receptor mutants on the activities of candesartan, telmisartan and eprosartan. The activities (inverse agonism or activity switch from inverse agonism towards agonism) of (A) candesartan, (B) telmisartan and (C) eprosartan at a concentration of 10 μM for each ARB in COS-1 cells transfected with N111G-AT 1 receptors, single mutants in N111G-AT 1 receptors and double mutants in N111G-AT 1 receptors are shown. Double mutants were constructed by making two additional independent mutations in N111G-AT 1 receptors that significantly attenuated the inverse agonist activity or switched activity from inverse agonism towards agonism. The agonist and inverse agonist activities are expressed as a percentage of the constitutive activity of vehicle-treated cells expressing N111G-AT 1 receptors and each N111G-AT 1 receptor mutant. The constitutive activities of vehicle-treated cells expressing N111G-AT 1 receptors and each N111G-AT 1 receptor mutant were defined as 0%. Data represent mean ± SEM of independent experiments [candesartan: n = 16 (N111G/K199Q, N111G/H256A and N111G/Q257A), n = 12 (N111G), n = 8 (N111G/V108I, N111G/A163T, N111G/E173A and N111G/K199Q/H256A) and n = 6 (all other mutants); telmisartan: n = 12 (N111G), n = 8 (N111G/K199Q, N111G/H256A, N111G/Q257A, N111G/S109T/A163T and N111G/A163T/N295A) and n = 6 (all other mutants); and eprosartan: n = 10 (N111G), n = 8 (N111G/K199Q, N111G/H256A, N111G/Q257A, N111G/S109T/A163T and N111G/A163T/ N295A) and n = 6 (all other mutants)]. Group sizes are not equal in Figure 4 . The reason for this is that data of some groups showed large SEM when n is 6 per group, and we had to examine additional experiments to confirm exact value for these groups. * P < 0.05, significantly different from N111G-AT 1 receptors; †, additive effect; one-way ANOVA followed by Bonferroni's or Dunnett's post hoc tests.
N111G-AT 1 receptors on the inverse agonist activity of candesartan were different from those observed for similar mutations in WT-AT 1 receptors. Contrary to the effects observed for the A163T, Y292A and N295A mutations, the N111G/A163T and N111G/N295A mutations switched activity towards agonism for candesartan, while the N111G/Y292A mutation significantly increased the inverse agonist activity of candesartan. The inverse agonist activity of candesartan was significantly increased by an additional mutation, namely, N111G/K199Q. The effects of all mutations in N111G-AT 1 receptors on the inverse agonist activity of telmisartan were completely different from those observed for similar mutations in WT-AT 1 receptors. Contrary to the effects observed for the V108I, A163T, F182A, Q257A, Y292A and N295A mutations in WT-AT 1 receptors, the N111G/V108I, N111G/A163T, N111G/F182A, N111G/Q257A and N111G//N295A mutations switched activity towards agonism for telmisartan, while the N111G/Y292A mutation significantly increased the inverse agonist activity of telmisartan. The inverse agonist activity of telmisartan was significantly increased by an additional mutation, namely, N111G/K199Q. The N111G/V108I, N111G/E173A, N111G/ K199Q, N111G/H256A, N111G/Q257A and N111G/Y292A mutations significantly decreased the inverse agonist activity of eprosartan. However, the effects of other mutations in N111G-AT 1 receptors on the inverse agonist activity of eprosartan were different from those observed for mutations in WT-AT 1 receptors. Contrary to the effects observed for the V108I, S109T and N295A mutations in the WT-receptors, the N111G/V108I mutation significantly decreased the inverse agonist activity of eprosartan, while the N111G/S109T and N111G/N295A mutations did not alter the inverse agonist activity of eprosartan. and Tyr292 TM7 in N111G-AT 1 receptors are critical residues responsible for the inverse agonist activity of eprosartan.
To determine the combinational interactions between the residues responsible for inverse agonism of N111G-AT 1 receptors, the effects of triple mutations on the inverse agonist activities of the various ARBs were examined. The mutations N111G/S109T/A163T, N111G/S109T/H256A, N111G/S109T/ N295A, N111G/A163T/H256A, N111G/A163T/N295A, N111G/ K199Q/H256A and N111G/H256A/N295A demonstrated sufficient constitutive activity, as previously described (Takezako et al., 2015) , and thus, the effects of these mutations on the inverse agonist activities of the ARBs were examined (Figure 4) . The N111G/K199Q/H256A mutation additively decreased the inverse agonist activity of eprosartan. The N111G/A163T/ N295A mutation additively increased the activity switch from inverse agonism towards agonism for both candesartan and telmisartan. No other triple mutations exhibited combined effects on the inverse agonist activities of any of the three ARBs. These results suggest that interactions between Lys199 TM5 and His256 TM6 in N111G-AT 1 receptors are important for the inverse agonist activity of eprosartan, while interactions between Ala163 TM4 and Asn295 TM7 are important for the activity switch from inverse agonism towards agonism for candesartan and telmisartan.
Molecular model of docking of ARBs to WT-AT 1 receptors
To examine whether the residues targeted in our study actually interact with candesartan, telmisartan and eprosartan, molecular models of AT 1 receptors were employed. The molecular models were developed based on the crystal structure of human AT 1 receptors bound to the biphenyl-tetrazole ARB ZD7155, as described in the Methods section (Zhang et al., 2015) . We used the human AT 1 receptors structure, as the overall sequence homology of rat and human AT 1 receptors is 95%, and all of the residues examined in this study are the same as those of human AT 1 receptors. The docking models of the three ARBs are shown in Figure 5 . The binding poses for the three ARBs in AT 1 receptors were predicted by energy-based docking simulation studies. The nature of the interaction with AT 1 receptors is different for each of the ARBs owing to their distinct chemical structures. However, all three ARBs bind in similar orientations and engage in interactions with critical residues, including Arg167 ECL2 (Takezako et al., 2015; Zhang et al., 2015) . As we previously demonstrated that Arg167 ECL2 is critical for binding ARBs and Ang II (Noda et al., 1995; Takezako et al., 2004; Zhang et al., 2015; Takezako et al., 2017) , the effects of Arg167 ECL2 mutations on the binding affinities and inverse agonist activities of the ARBs were not investigated in the present study, to avoid duplication of negative binding results. Of the 12 residues examined in this study , Val108  TM3 , Ser109  TM3 ,   Tyr113  TM3 , Ala163  TM4 , Phe182  ECL2 , Tyr184  ECL2 , Lys199  TM5 ,   His256  TM6 , Gln257  TM6 , Tyr292  TM7 and Asn295  TM7 were found to be present in the common ARB-binding pocket. One residue, namely, Glu173 ECL2 , lacks reliable X-ray diffraction density in the AT 1 receptor structure; therefore, this residue is not indicated in Figure 5A -D. As shown in Figure 5 and the recently solved AT 1 receptor structure (Zhang et al., 2015) , the residues in TM helices I-VII, as well as extracellular loop 2 (ECL2), comprise the canonical ARB binding pocket. . The ARBs are shown as sticks with red (candesartan), magenta (telmisartan) and blue (eprosartan) carbons. Side-chain positions of residues investigated in this report are located within a 10 Å pocket for each ARB. In each ARB-bound model, single side-chain mutations affecting binding with a >3-fold change in K i are indicated by a thick green colour and bold label, both in the ground state (WT-AT 1 receptor) and active state (N111G-AT 1 receptor). A red residue label denotes a significant effect on inverse agonism for IP formation in WT-and N111G-AT 1 receptors. Highlighted residues shown as yellow spheres denote a unique influence on inverse agonism for IP formation in the specified state of AT 1 receptors for the particular ARB. (Kellici et al., 2016a,b) ; the amino group of this residue may reach the carboxyl group of eprosartan by forming salt bridges or may interact through water-mediated interactions with the phenyl scaffold, which may explain the reduced binding affinity and inverse agonist activity of eprosartan upon mutation of Lys199 TM5 (Takezako et al., 2015; Zhang et al., 2015; Takezako et al., 2017) . The residues Tyr35 TM1 , Trp84 TM2 , Arg167 ECL2 , Met284 TM7 , Pro285
TM7
and Ile288 TM7 were not targeted in this study and are therefore not shown in Figure 5 .
Effect of mutations on binding and inverse agonism in the superimposed ARB docking models
Molecular modelling of the active state of N111G-AT 1 receptors is difficult, as the long timescale required for molecular dynamics simulations of GPCRs is untenable (Manglik and Kobilka, 2014) . Simulations on shorter timescales showed subtle changes in the binding pocket of AT 1 receptors with low P values (Takezako et al., 2015) . In addition, comparisons between multiple active and inactive crystal structures of GPCRs have been reported and demonstrated only subtle conformational differences in the ligand-binding pockets of the ground and active states (Katritch et al., 2013) . Therefore, our approach does not involve modelling N111G-AT 1 receptors. The docking of N111G-AT 1 receptors is shown in identical pose with WT-AT 1 receptors. Colour-highlighted residues shown in Figure 5B -D are based on the experimental data (effect of mutated residues on the binding affinity and inverse agonist activity) for each ARB in the ground and active states. Superposition of the experimental data for WT-and N111G-AT 1 receptors is shown in Figure 5B- (Noda et al., 1996; Balmforth et al., 1997; Groblewski et al., 1997; Zhang et al., 2015) . , and this network of residues is likely to convey the conformational changes in the ligand-binding pocket to the cytoplasmic domain coupling to the G proteins during the activation process of AT 1 receptors (Takezako et al., 2015; Takezako et al., 2017) . This network of residues may also affect the inter-helical interactions required for the binding and inverse agonist activity of ARBs. (Takezako et al., 2015) (Figure 3) , interaction with this residue is therefore not a common feature of the inverse agonist activity of ARBs. Previous structure-function studies using a substituted cysteine accessibility method proposed that both rotational and translational motion of TM2, TM3, TM5, TM6 and TM7 occurred in N111G-AT 1 receptors, which mimics the active state of AT 1 receptors (Boucard et al., 2003; Martin et al., 2004; Martin et al., 2007; Domazet et al., 2009) . In the active state of AT 1 receptors, an Asn46-Asp74-Asn295 H-bond network is proposed to form, which involves additional interacting residues around Asn111 TM3 and Asn295 TM7 (Cabana et al., 2013 Interaction with TM3, TM4, ECL2, TM5, TM6 and TM7 residues participates in the inverse agonist activity of candesartan in the active state, while interaction with TM3, ECL2, TM6 and TM7 residues participates in the inverse agonist activity of candesartan in the ground state. Interaction with TM3, TM4, ECL2, TM5, TM6 and TM7 residues participates in the inverse agonist activity of telmisartan in the active state, while interaction with ECL2, TM6 and TM7 residues participates in the inverse agonist activity of telmisartan in the ground state. Finally, interactions with TM3, ECL2, TM5, TM6 and TM7 residues participate in the inverse agonist activity of eprosartan in the active state, while interactions with TM3, ECL2, TM6 and TM7 residues participate in the inverse agonist activity of eprosartan in the ground state. These comparisons suggest that 'leaning' of the three ARBs on TM helices and ECL2 changes upon transition of AT 1 receptors from the ground to active state, similar to the effects observed for losartan, EXP3174, valsartan and irbesartan (Takezako et al., 2015) . This change in 'leaning' on TM helices and ECL2 is significant for candesartan and telmisartan, as well as for losartan, EXP3174, valsartan and irbesartan (Takezako et al., 2015) . Therefore, destabilization of the Asn46-Asp74-Asn295 H-bond network and reduction in hydration of the TM core by the biphenyl-tetrazole ARBs and telmisartan may be weak, which may explain the decreased inverse agonist activity for the active state of AT 1 receptors. In contrast, as the change in 'leaning' of eprosartan on TM helices and ECL2 seems to be subtle, eprosartan can strongly destabilize the Asn46-Asp74-Asn295 H-bond network and reduce the hydration of the TM core, which may explain the robust inverse agonist activity observed for eprosartan for the active state of AT 1 receptors. We observed that mutation of all or some of the residues Val108 TM3 , Ala163 TM4 , Phe182 ECL2 , Gln257 TM6 and Asn295 TM7 switched the activity of candesartan and telmisartan from inverse agonism towards agonism in N111G-but not in WT-AT 1 receptors (Figure 4 ), consistent with results observed for losartan, EXP3174, valsartan and irbesartan. Although the exact mechanism for the change in ligand-dependent function of the receptor is unclear, we recently suggested possible mechanisms for this phenomenon (Takezako et al., 2015; Takezako et al., 2017) . Briefly, bulky substitution of Val108 TM3 and Ala163 TM4 may result in steric hindrance in the ARB-induced inactive AT 1 receptor conformation, while removal of the side chains of Gln257 TM6 , Asn295 TM7 and Phe182 ECL2 may weaken interactions with the ARBs, which may hydrate the hydrophobic core and stabilize the Asn46-Asp74-Asn295 H-bond network. Although elucidation of the precise mechanism of such a transformation of pharmacological activity of ARBs requires additional biophysical analysis, such as a comparison of bound water molecules in the active and inactive states, current resolution of the AT 1 receptor structure is inadequate to perform this kind of analysis. Although saturation mutagenesis for the above residues, combined with ligand binding and receptor functional assays, are indirect methods, this type of study alternatively may clarify the potential mechanism of this phenomenon.
Prior to the present study, the biphenyl-tetrazole ARBs have been known to exhibit robust inverse agonist activity for the ground state of AT 1 receptors, but the inverse agonist activity of these ARBs is strongly decreased upon transition of AT 1 receptors to the active state. Novel finding of the present study is that the non-biphenyl-tetrazole ARB eprosartan causes robust inverse agonist activity for both the ground and active states of AT 1 receptors. Although N111G mutation, mechanical stress and autoantibody activate the AT 1 receptor, conformation of N111G mutant, mechanically activated AT 1 receptors and autoantibody-activated AT 1 receptors may not be identical. However, eprosartan remarkably shows robust inverse agonist activity for both WT and N111G mutant receptors, suggesting that eprosartan can stabilize various conformational states of AT 1 receptors between ground and active state in an inactive state to similar degrees. Therefore, we suppose that eprosartan can show potent inverse agonist activity for various activated state of AT 1 receptors in living cells. Transition of AT 1 receptors to the active state largely changes the ligand-receptor interactions for the biphenyl-tetrazole ARBs and telmisartan, which decreases their respective inverse agonist activities for the active state of AT 1 receptors. However, active-state transition of AT 1 receptors causes only subtle changes in ligand-receptor interactions for eprosartan. Thus, eprosartan is able to conserve the robust inverse agonist activity for the active state of AT 1 receptors. Subtle changes in ligand-receptor interactions for eprosartan may explain the observation that eprosartan activity does not switch from inverse agonism towards agonism upon mutation of residues Val108 TM3 , Ala163 TM4 , Phe182 ECL2 , Gln257 TM6 and Asn295 TM7 in the active state of AT 1 receptors. As eprosartan may exhibit enhanced therapeutic effects for diseases caused by agonist-independent activation of AT 1 receptors, such as hypertension, cardiac hypertrophy, renal transplantation, primary aldosteronism and systemic sclerosis, additional experimental and clinical studies need to be performed to compare the effects of eprosartan with those of other ARB.
As we have focused on inverse agonism of the ARBs on G qprotein signalling pathway, the present study has limitations. The AT 1 receptor has G q -protein-independent signalling pathways such as β-arrestin-mediated pathway as well as G qprotein signalling pathway. Effects of AT 1 receptor-mediated β-arrestin signalling varies depending on the organ. For example, in the heart, AT 1 receptor-mediated β-arrestin signalling has been shown to cause effects opposite to those of G q -protein-mediated signalling. The β-arrestin signalling causes protective effect for cardiac hypertrophy (Teixeira et al., 2017) and heart failure (Ryba et al., 2017) , whereas G qmediated signalling causes cardiac hypertrophy (Nakayama et al., 2010; Matsushita et al., 2014) and exacerbates heart failure (Matsushita et al., 2014) . On the other hand, in the adrenal grand, AT 1 receptor-mediated G q -protein signalling and β-arrestin signalling have shown to have the same effect. Recent study showed that all commercially available ARBs prevent Ang II-stimulated β-arrestin signalling (Dabul et al., 2015) . In addition, although effect of the ARBs on β-arrestin signalling in the N111G-AT 1 receptors has not been examined, recent studies have shown that losartan and telmisartan prevent β-arrestin signalling by the mechanically activated AT 1 receptors (Rakesh et al., 2010; Tang et al., 2014) , indicating that these ARBs are inverse agonists for β-arrestin signalling as well as G q protein signalling in active state of AT 1 receptors. Therefore, pharmacological activity of the ARBs on β-arrestin signalling needs to be examined in a future study.
